Get the Stockscreener App
14.37
1.13%
0.16
After Hours:
14.37
Aurinia Pharmaceuticals Inc stock is traded at $14.37, with a volume of 876.30K.
It is up +1.13% in the last 24 hours and down -0.42% over the past month.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing aritinercept, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
See More
Previous Close:
$14.21
Open:
$14.53
24h Volume:
876.30K
Relative Volume:
0.89
Market Cap:
$1.91B
Revenue:
$283.06M
Net Income/Loss:
$287.20M
P/E Ratio:
6.9183
EPS:
2.0771
Net Cash Flow:
$135.69M
1W Performance:
+2.06%
1M Performance:
-0.42%
6M Performance:
+11.83%
1Y Performance:
+65.74%
1-Day Range:
$14.29
$14.84
1-Week Range:
$13.85
$15.22
52-Week Range:
$6.825
$16.54
Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile
Name
Aurinia Pharmaceuticals Inc
Sector
Industry
Phone
250-744-2487
Address
#140, 14315 - 118 AVENUE, EDMONTON, BC
Compare AUPH vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AUPH
Aurinia Pharmaceuticals Inc
|
14.37 | 1.89B | 283.06M | 287.20M | 135.69M | 2.0771 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-03-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Nov-07-25 | Upgrade | Jefferies | Hold → Buy |
| Nov-05-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-30-25 | Resumed | H.C. Wainwright | Buy |
| Nov-04-22 | Downgrade | Oppenheimer | Outperform → Perform |
| May-05-22 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-10-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-28-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-25-21 | Reiterated | H.C. Wainwright | Buy |
| Nov-03-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| May-05-20 | Initiated | Cowen | Outperform |
| Jan-10-20 | Initiated | Jefferies | Buy |
| Dec-16-19 | Reiterated | H.C. Wainwright | Buy |
| Mar-16-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Feb-08-18 | Initiated | RBC Capital Mkts | Outperform |
| Oct-30-17 | Reiterated | H.C. Wainwright | Buy |
| May-18-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-11-17 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-22-17 | Reiterated | FBR & Co. | Outperform |
| Dec-30-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-17-16 | Reiterated | H.C. Wainwright | Buy |
| Jun-30-16 | Initiated | H.C. Wainwright | Buy |
| May-08-15 | Initiated | MLV & Co | Buy |
View All
Aurinia Pharmaceuticals Inc Stock (AUPH) Latest News
[SCHEDULE 13D/A] Aurin... - Stock Titan
AUPH stock rallies after CEO shake-up: Retail bulls bet on turnaround - MSN
AUPH SEC FilingsAurinia Pharmace 10-K, 10-Q, 8-K Forms - Stock Titan
Aurinia names board chair Kevin Tang as new CEO By Investing.com - Investing.com Canada
Mutiny At Aurinia Pharmaceuticals? Biotech Rallies On C-Suite Shake-Up - Investor's Business Daily
Aurinia appoints Kevin Tang as CEO with zero compensation By Investing.com - Investing.com India
Why Aurinia Pharmaceuticals stock is surging Monday morning - MSN
Aurinia Reshapes C-Suite as Investor Kevin Tang Takes CEO Role Without Pay - TipRanks
Aurinia Pharmaceuticals Announces New CEO and Leadership Team Amid Continued Growth in Autoimmune Disease Therapies 1 - Minichart
Aurinia appoints Kevin Tang as CEO with zero compensation - Investing.com
MKT Capital Applauds Aurinia Pharmaceuticals’ Management Transition - FinancialContent
Why Aurinia Pharmaceuticals Stock Is Surging Monday Morning - Benzinga
Aurinia Reshapes Executive Team as Board Chair Kevin Tang Becomes CEO - TipRanks
Aurinia Pharmaceuticals Inc. Appoints Michael Hearne as Chief Financial Officer - marketscreener.com
Aurinia Pharmaceuticals Inc. Announces Executive Appointments - marketscreener.com
Aurinia Pharmaceuticals Inc. Announces Chief Executive Officer Changes - marketscreener.com
Aurinia names board chair Kevin Tang as new CEO - Investing.com
Aurinia appoints Kevin Tang as CEO and Ryan Cole as COO - TradingView
Aurinia (NASDAQ: AUPH) installs Kevin Tang as CEO amid broad C-suite exits - Stock Titan
Aurinia Announces Management Transition - The Joplin Globe
(AUPH) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Aurinia names Kevin Tang as new CEO, retail bet on turnaround | Tap to know more | Inshorts - Inshorts
Aurinia raises 2025 revenue outlook to $270M as LUPKYNIS accelerates market penetration - MSN
Investors - Aurinia Pharmaceuticals Inc.
AUPH Stock Rallies After CEO Shake-Up: Retail Bulls Bet On Turnaround - Stocktwits
Aurinia Pharmaceuticals (NASDAQ:AUPH) Stock Passes Below 200-Day Moving AverageHere's What Happened - MarketBeat
Aurinia Pharmaceuticals (AUPH) stock drops after strong quarter, softer forward revenue targets - MSN
AUPH stock gains on Aurinia Pharma’s Q4 beat, but 2026 guidance misses estimates - MSN
Buybacks Report: What dividend growth rate does Aurinia Pharmaceuticals Inc offerMarket Activity Summary & Verified Momentum Stock Ideas - baoquankhu1.vn
Market Trends: Will Aurinia Pharmaceuticals Inc benefit from government policySell Signal & Short-Term Trading Opportunity Alerts - baoquankhu1.vn
Is Aurinia Pharmaceuticals (AUPH) Pricing Reflect Long Term Value After 71% One Year Gain - Yahoo Finance
Responsive Playbooks and the AUPH Inflection - Stock Traders Daily
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) Receives Average Recommendation of "Hold" from Analysts - MarketBeat
Aurinia Pharmaceuticals (NASDAQ:AUPH) Stock Passes Below 50-Day Moving AverageShould You Sell? - MarketBeat
Aurinia Pharma’s Wild Ride: What AUR’s Lupus Bet Means For You - AD HOC NEWS
A Look At Aurinia Pharmaceuticals (AUPH) Valuation After Strong Growth And Optimistic 2026 Guidance - simplywall.st
The Bull Case For Aurinia Pharmaceuticals (AUPH) Could Change Following Strong 2025 Results And Upbeat 2026 Outlook - Sahm
Aurinia Pharmaceuticals Earnings Strength And Valuation Gap Attract Investor Attention - Sahm
Implied Volatility Surging for Aurinia Pharmaceuticals Stock Options - MSN
Aug Breakouts: Why is Aurinia Pharmaceuticals Inc stock going upExit Point & Daily Oversold Bounce Ideas - baoquankhu1.vn
Aurinia Pharmaceuticals: Waiting For Another Opportunity (Downgrade) (NASDAQ:AUPH) - Seeking Alpha
Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress - Zenopa
Aurinia Pharmaceuticals (NASDAQ:AUPH) Director Buys $7,224,981.61 in Stock - MarketBeat
Aurinia Pharmaceuticals Inc (AUPH): Investor Outlook Reveals 19.63% Potential Upside - DirectorsTalk Interviews
Tang Capital LPs tied to Aurinia (NASDAQ: AUPH) buy 900K shares - Stock Titan
Assessing Aurinia Pharmaceuticals (AUPH) Valuation After Recent Share Price Swings - simplywall.st
Tang Capital boosts Aurinia (AUPH) stake to 9.2% ownership - Stock Titan
Aurinia (NASDAQ: AUPH) CFO gets stock, options; covers tax bill - Stock Titan
Aurinia (AUPH) COO receives stock grants and settles taxes with shares - Stock Titan
Aurinia (NASDAQ: AUPH) CEO receives major option grant and withholds shares for taxes - Stock Titan
Aurinia (AUPH) CMO awarded new stock options and share grant - Stock Titan
Aurinia Pharmaceuticals Inc Stock (AUPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):